Replies to post #178011 on Innovation Pharmaceuticals Inc (IPIX)

[baytdr]

it seems to me that B OM deserves the Co.'s highest priority. Nothing on the market to compete with, if final P2 results are similar to what we've seen to date the trial should qualify for BTD and would recruit quickly due to simplicity non-invasive delivery method and serious affliction it prevents. I'd sure sign up if I was a candidate. I think BP will be all over this one very soon. The safety profile is actually quite good and substantial if you consider all the trials it's been involved in.

[nerby]

Amatuer (in French amatuer roughly translates as "killer of love" as opposed to amateur = "lover of" but that's neither here nor there) I get your general premise that "the market" usually knows best, and that if a company like CTIX shows little SP appreciation despite reporting good progress, then "the market" must know something better than I might as an individual investor. That general premise falters a bit when considering the occasional broad market decline or crash that comes along periodically, and that no one, including "the market", saw coming. More to the point, if the market always knows best and puts its value appropriately on individual companies at any given time, then why would PCYC be valued by the market at $5/share in Feb 2011 and then give it a value of $25 a year later? How did the market miss such a discrepancy? In REGN's case, the market obviously missed that a stock that could be bought for $13/share in 2009 would be worth $575/share 6 years later. What changed in both cases of course was that the science kept moving forward, partnerships were formed, cash was more plentiful, etc. I simply don't buy that the market always knows best, especially about CTIX. In fact I'm betting heavily that in the isolated case of CTIX, in fact I know quite a bit more than "the market" does. My 2 cents.

[MinnieM]

Go back to this interview and read about how management thinks.

Interview With New Cellceutix President Dr A Bertolino
https://seekingalpha.com/article/3988240-interview-new-cellceutix-president-dr-bertolino

Q: Shareholders are frustrated with the pace of development of Brilacidin for ABSSSI. Can you give me your view on Brilacidin and moving it into a pivotal clinical trial?

"A: For starters, from what I've learned about Brilacidin recently, it is an incredibly promising drug for many, many applications. I believe that Brilacidin is a drug that is an ideal example where multiple potential indications can evolve in parallel as I mentioned earlier. It is also currently in active clinical trials for oral mucositis and ulcerative proctitis. The most effective strategy for further development will likely emerge once we have perspectives across all of these indications.

As it stands currently for ABSSSI, we have planned a response to FDA for the Special Protocol Assessment, but we are delaying its submission. I'll explain why.

In my limited time so far at Cellceutix, I have been debriefed on all ongoing communications with the FDA and other pharmaceutical companies. I know that there is interest from different companies for different compounds in the pipeline. We are estimating that Phase 3 studies will cost approximately $30 million over about two years, which means we need to raise some additional capital to conduct that research and move forward with all the other drugs we're developing. I also believe that the Cellceutix share price is artificially depressed because of: a lawsuit that we believe was without merit yet took time and resources to reach its recent dismissal; and a generally negative bias towards the biotech sector on Wall Street.

That said, I believe that it is best for us to focus on the other more cost-effective trials at present and wait for upcoming milestones that can assist in recovery of CTIX share value so as to minimize dilution when raising capital for the ABSSSI trial. We already know that Brilacidin compares favorably to daptomycin in treating ABSSSI and have two other trials, oral mucositis and ulcerative proctitis, ongoing with the compound to further prove its merit in treating other indications. In my view, it is most prudent to circle back around to ABSSSI when we can draw upon available capital at a more shareholder-friendly valuation. Because of all the prep work, we can then squeeze that trigger and move forward expeditiously."

In Reply to 'Amatuer17'
That was not the point - it was the twist and flip flop carried by Leo.

If the P3 for B-OM need higher number of patients and needs higher cost - Leo may drop B-OM like he dropped B-ABSSI - and may move to B-UP P2b as new alternative

He has shown his liking for jumping onto new trials without taking a single product to completion

Look at market response - yawn
As market just does not believe in his big PRs

Any other company with good B-OM and possibility of BTD

[FlashingLeather]

It's interesting that what you deem flipping, flopping, twisting, and chaotic management, I find extremely compelling for a sizable investment in CTIX. The imbedded optionality in management's ability to define business strategy by navigating via a multitude of possible forward decision paths under conditions of constrained resources and future uncertainties has tremendous worth, both from a position of value maximization AND risk mitigation.

Those able to see past a current myopic market environment characterized by 1) a short-term time horizon, and 2) a desire for visibility in how future development will be funded (i.e. cash position), will be rewarded quite handsomely in the future.

That was not the point - it was the twist and flip flop carried by Leo.